Baseline and Longitudinal Pan-Immune-Inflammation Value Compared with Other Inflammatory Indices in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study. (PubMed, Sisli Etfal Hastan Tip Bul) - Oct 3, 2026 - "We retrospectively analyzed 205 patients treated at a single tertiary center for non-small-cell lung cancer, renal cell carcinoma, melanoma, or other solid tumors who received an ICI (90.2% nivolumab)...Baseline and on-treatment absolute PIV values, but not early relative changes in PIV, are independently associated with survival outcomes in patients receiving ICIs, with prognostic performance comparable to that of established inflammatory indices. PIV may serve as a simple, repeatable biomarker to support risk stratification during ICI therapy."
Checkpoint inhibition • IO biomarker • Journal • Retrospective data • Genito-urinary Cancer • Inflammation • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Bahadir Koylu; Bulent Yildiz; Cevat Ilteris Kikili; Duygu Bayir Garbioglu; Fatih Kemik; Fatih Selçukbiricik; Feyzi Kangul; Lutfiye Demir; Murat Dinçer; Nazan Demir; Tugrul Burak Genc; Yasemin Sagd?c Karateke
|